Leidos · 3 hours ago
Proposal Editor II with TS/SCI Clearance
Leidos is a company that delivers innovative solutions through its diverse and talented workforce. They are seeking a Proposal Editor II with a TS/SCI clearance to ensure technical consistency and clarity across proposals, while also managing editing schedules and collaborating with proposal teams.
ComputerGovernmentInformation ServicesInformation TechnologyNational SecuritySoftware
Responsibilities
Act as the editing Point of Contact for assigned proposals, RFIs or White Papers
Prepare as necessary given the level of edit and the proposal size (skim Section L, Section M, SOW or PWS, win themes and discriminators; create individual proposal style guide if required)
Work with Proposal Manager and Proposal Coordinator to complete the Editing Intake Form
Negotiate timing and level of edit with the Proposal Manager and Proposal Coordinator as needed
Attend meetings at the Proposal Manager’s request
Edit according to rules of grammar, the Leidos House Style Guide, the proposal-specific style, and the level of edit and acronym treatment
Develop and maintain acronym lists
Perform consistency checking at least on sections that are split among multiple editors
Complete edits in a timely manner
Support Evaluation Notice (EN) and Final Proposal Revision (FPR) responses, as required
Qualification
Required
Bachelor's degree in English, Linguistics, or related subject and 4+ years of editing experience. Additional years of experience will be considered in lieu of a degree
Ability to effectively communicate with proposal leaders and authors
Excellent grasp of grammar, punctuation, and spelling
Experience with AP style
Excellent comprehension of passive-to-active conversion, parallel structure, and proper placement of modifiers
Skilled in Microsoft and Adobe products
Able to work overtime and weekends, as required, to meet proposal schedules
Active TS/SCI clearance
Preferred
Skilled in SharePoint
Knowledge of technical terminology
Company
Leidos
Leidos is a Fortune 500® innovation company rapidly addressing the world’s most vexing challenges in national security and health.
Funding
Current Stage
Public CompanyTotal Funding
unknown2025-02-20Post Ipo Debt
2013-09-17IPO
Recent News
MarketScreener
2025-12-16
2025-12-16
Company data provided by crunchbase